Effect of allogeneic pure platelet-rich plasma, sodium cloxacillin, and their combination for the treatment of subclinical mastitis in crossbred cows

被引:0
|
作者
Lopez, Catalina [1 ]
Duque-Madrid, Paulo Cesar [2 ]
Ceballos-Marquez, Alejandro [2 ]
Carmona, Jorge U. [3 ]
机构
[1] Univ Caldas, Dept Salud Anim, Grp Invest Patol Clin Vet, Manizales, Colombia
[2] Univ Caldas, Dept Prod Agr, Grp Invest Cal Leche & Epidemiol Vet, Manizales, Colombia
[3] Univ Caldas, Dept Salud Anim, Grp Invest Terapia Regenerat, Manizales, Colombia
关键词
platelet-rich plasma; bovine; subclinical mastitis; gram-positive bacteria; growth factors; cytokines; SOMATIC-CELL COUNT; INTRACELLULAR STAPHYLOCOCCUS-AUREUS; BOVINE ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; CYTOKINES TNF-ALPHA; NF-KAPPA-B; ECONOMIC-IMPACT; MILK-YIELD; THERAPY; CURE;
D O I
10.3389/fvets.2024.1432354
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Introduction: Bovine subclinical mastitis (SCM) caused by Gram-positive bacteria is a major cause of economic loss in the dairy industry, exacerbated in situations where antimicrobial resistance is present. Pure platelet-rich plasma (P-PRP) may be a therapeutic alternative for SCM, when used alone or with antibiotics, such as sodium cloxacillin (SC). This study aimed 1) to evaluate the therapeutic efficacy of allogeneic P-PRP, SC, and their combination (P-PRP+SC) in cows with SCM caused by Staphylococcus aureus and by streptococci (Staphylococcus aureus and S. dysgalactiae); 2) to determine the concentrations of somatic cells (SCC), interleukin 1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha) and TGF-beta(1) in milk samples of the cows. Methods: 130 cows from 4 dairy herds completed the study, of which 40 cows were treated with P-PRP (10 mL), 28 cows with SC (5g), 36 with P-PRP+SC (10mL/5g), and 26 did not receive no treatment (negative control group, NCG). Results: The overall bacteriological cure was observed in 10/40 (25%) cows in the P-PRP group, 9/28 (32.14%) animals in the SC group, 26/36 (72.22%) cows in the P-PRP+SC group, and 10/26 (38.46%) animals in the NCG. SCM caused by S. aureus (82/130, 63.08%), was cured in 6/24 (25%) cows treated with P-PRP, 7/24 (29.2%) cows treated with SC, 8/16 (50%) animals treated with P-PRP+SC, and in 8/18 (44.4%) cows in NCG. For SCM caused by the streptococci (48/130, 36.91%), the cure was achieved in 4/12 (33.3%) cows treated with P-PRP, 2/4 (50%) cows treated with SC, 18/20 (90%) cows treated with P-PRP+SC, and in 2/8 (25%) cows of the NCG. SCC was significantly (p < 0.001) affected by the treatment, herd, cure, bacteria group, and number of calvings factors. IL-1 beta milk concentrations were significantly (p < 0.001) influenced by treatment and farm factors, and the interaction between these factors. TNF-alpha milk concentrations were significantly (p < 0.001) influenced by time factor. TGF-beta(1) milk concentrations were significantly affected by the time and cure factors. Conclusion: The combination of P-PRP and SC showed the best therapeutic response (90%) against bovine SCM caused by streptococci. However, none of the treatments showed an effective therapeutic response against S. aureus.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Matriderm and platelet-rich plasma combination in the treatment of recurrent carpal tunnel syndrome: a new approach
    Bozkurt, Mehmet
    Tatar, Burak Ergun
    Karakol, Percin
    Sezgic, Melihcan
    Uslu, Can
    Solak, Hazal Tas
    Gelbal, Caner
    EUROPEAN JOURNAL OF PLASTIC SURGERY, 2022, 45 (02) : 299 - 306
  • [22] Platelet-rich plasma and fractional CO2 laser combination treatment for face rejuvenation
    Tsiatoura, Amalia
    Vekris, Anastasios
    Zafeiratou, Dimitra
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB19 - AB19
  • [23] Treatment of auricular keloids by triple combination therapy: Surgical excision, platelet-rich plasma, and cryosurgery
    Azzam, Ehab Zaki
    Omar, Salma Samir
    JOURNAL OF COSMETIC DERMATOLOGY, 2018, 17 (03) : 502 - 510
  • [24] Matriderm and platelet-rich plasma combination in the treatment of recurrent carpal tunnel syndrome: a new approach
    Mehmet Bozkurt
    Burak Ergün Tatar
    Perçin Karakol
    Melihcan Sezgiç
    Can Uslu
    Hazal Tas Solak
    Caner Gelbal
    European Journal of Plastic Surgery, 2022, 45 : 299 - 306
  • [25] Treatment of periapical inflammatory lesion with the combination of platelet-rich plasma and tricalcium phosphate:: A case report
    Demiralp, B
    Keçeli, HG
    Muhtarogullari, M
    Serper, A
    Demiralp, B
    Eratalay, K
    JOURNAL OF ENDODONTICS, 2004, 30 (11) : 796 - 800
  • [26] Effect of light-emitting diodes, platelet-rich plasma, and their combination on the activity of sheep tenocytes
    Jihad A. M. Alzyoud
    Saleh A. Al Najjar
    Seham Talat
    Basha’er Abu-Irmaileh
    Yasser Bustanji
    Abd Al-Rahman S. Al-Shudiefat
    Lasers in Medical Science, 2019, 34 : 759 - 766
  • [27] Effect of light-emitting diodes, platelet-rich plasma, and their combination on the activity of sheep tenocytes
    Alzyoud, Jihad A. M.
    Al Najjar, Saleh A.
    Talat, Seham
    Abu-Irmaileh, Basha'er
    Bustanji, Yasser
    Al-Shudiefat, Abd Al-Rahman S.
    LASERS IN MEDICAL SCIENCE, 2019, 34 (04) : 759 - 766
  • [28] The bone regenerative effect of platelet-rich plasma in combination with an osteoconductive material in rat cranial defects
    Plachokova, AS
    van den Dolder, J
    Stoeling, PJ
    Jansen, JA
    CLINICAL ORAL IMPLANTS RESEARCH, 2006, 17 (03) : 305 - 311
  • [29] Effect of Freeze-Thawing Treatment on Platelet-Rich Plasma Purified with Different Kits
    Uchiyama, Ryoka
    Omura, Haruka
    Maehara, Miki
    Toyoda, Eriko
    Tamaki, Miyu
    Ogawa, Makoto
    Tanaka, Tatsumi
    Watanabe, Masahiko
    Sato, Masato
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [30] Observation on the effect of platelet-rich plasma combined with drugs in the treatment of herpes zoster neuralgia
    Zhou, Zenghua
    Hu, Xin
    Yan, Fangran
    Zhou, Yanhua
    He, Ruilin
    Ye, Xiaolong
    Jiang, Zongbin
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2024, 134 (06) : 628 - 634